Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent (NYSE: EVH) announced that its Compensation Committee approved a one-time inducement restricted stock unit award of 587,500 shares to Mario Ramos, who became Evolent's Chief Financial Officer effective January 2, 2026. The award was granted under NYSE Listing Rule 303A.08 because Ramos was not a prior employee.
The grant has a grant-date value of $2,350,000 and vests over three years: 34% on the first anniversary, 33% on the second and 33% on the third, contingent on continued employment through each vesting date.
Evolent Health (NYSE: EVH) and American Oncology Network announced a national partnership on Nov 6, 2025 to deploy a quality‑focused cancer care model that aims to reduce costs, speed treatment and remove prior authorization for providers who meet quality standards.
Key elements include gold‑carding providers who adhere to treatment pathways (eliminating most prior authorizations), an AI analytics platform called MiBA for personalized treatment insights, an aligned payment model to reward high‑quality care, and Evolent's care navigation program, Careology. The model will roll out in select markets in the year ahead.
Evolent Health (NYSE: EVH) reported Q3 2025 results: revenue of $479.5M, GAAP net loss of $26.9M and Adjusted EBITDA $38.96M (8.1%). The company added two new customer agreements in Q3, bringing year-to-date new contracts to 13 and now expects to launch more than $750M of new annualized revenue in 2026 with signed contracts preliminarily supporting $2.5B in 2026 revenue. Cash and equivalents were $116.7M at quarter end. Leadership changes include a new CFO, Mario Ramos, and a new Chief Strategy Officer effective Jan 1, 2026. Full-year 2025 guidance is now revenue $1.87B–$1.88B and adjusted EBITDA $144M–$154M. The company reiterated Q4 2025 revenue and adjusted EBITDA ranges.
Evolent (NYSE: EVH) will release its third quarter 2025 financial results on Thursday, November 6, 2025 after market close, followed by a conference call at 5:00 p.m. ET.
Shareholders can listen live and access an audio replay for 90 days on Evolent's investor relations website. Analysts may join the live Q&A via domestic dial-in 855.940.9467 or international 412.317.6034 (reference: "Evolent call").
Management will also present at upcoming investor conferences: UBS Global Healthcare in Palm Beach Gardens on Nov 11, 2025, Stephens Investment in Nashville on Nov 18, 2025, and Piper Sandler Healthcare in New York from Dec 2–4, 2025. Live audio webcasts and replays will be posted in the Events and Presentations section of the investor site as times become available.
Evolent Health (NYSE: EVH) has announced the sale of its value-based primary care business, Evolent Care Partners (ECP), to Privia Health Group for up to $113 million in cash. The transaction includes $100 million at closing and additional payments in Fall 2026 based on MSSP performance.
The strategic divestiture involves ECP's operations serving over 120,000 members through partnerships with 1,000+ physicians in the Medicare Shared Savings Program. The company plans to use proceeds to prepay senior term debt, expecting to improve annual cash flow by over $7 million.
Evolent reaffirmed its Q3 2025 guidance with revenue of $460-480 million and Adjusted EBITDA of $34-42 million, as well as full-year 2025 outlook of $1.85-1.88 billion in revenue and $140-165 million in Adjusted EBITDA, before accounting for the transaction impact.
Evolent Health (NYSE:EVH) has announced the pricing of $145.0 million of 4.50% convertible senior notes due 2031, with an option for an additional $21.75 million. The notes are convertible into cash, shares, or a combination at an initial conversion price of $13.53 per share, representing a 50% premium over the closing price.
The company will use approximately $100.2 million of the proceeds to repurchase $167.4 million of its existing 2025 Notes, and $40.0 million to repurchase shares at $9.02 per share. The transaction is expected to save over $9 million in annual interest expense while minimizing shareholder dilution with an effective conversion premium exceeding 130%.
Evolent Health (NYSE: EVH) has announced plans to offer $140.0 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $20.0 million. The company intends to use $100.0 million to repurchase a portion of its 1.50% convertible senior notes due 2025 and $40.0 million to repurchase Class A common stock.
The new notes, offered exclusively to qualified institutional buyers under Rule 144A, will be convertible into cash, Class A common stock, or a combination thereof. They will mature on August 15, 2031, with semiannual interest payments beginning February 15, 2026. Evolent maintains the right to terminate conversion rights after August 20, 2026, subject to specific stock price conditions.
Evolent Health (NYSE:EVH) reported Q2 2025 financial results with revenue of $444.3 million, down from $647.1 million in Q2 2024. The company posted a net loss of $51.1 million, compared to a $6.4 million loss in the prior year. Despite the revenue decline, Adjusted EBITDA margin improved to 8.5% from 8.0% year-over-year.
The company announced four new revenue agreements in Q2, bringing the year-to-date total to 11. For Q3 2025, Evolent expects revenue between $460-480 million and Adjusted EBITDA of $34-42 million. Full-year 2025 guidance was revised, with revenue projected at $1.85-1.88 billion and Adjusted EBITDA expected between $140-165 million.
Management highlighted strong customer retention and accelerating pipeline growth, expecting to exceed historical growth rates for 2026.
Evolent Health (NYSE:EVH), a healthcare company focused on complex conditions management, has scheduled its Q2 2025 earnings release for August 7, 2025, after market close. The company will host a conference call at 5:00 PM ET the same day.
Shareholders can access the live broadcast through Evolent's investor relations website. Analysts can participate by dialing 855.940.9467 (US) or 412.317.6034 (International). Additionally, EVH's management team will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2025.
Evolent Health (NYSE: EVH) announced two key leadership appointments to strengthen its clinical and financial teams. Dr. David Lim joins as chief clinical officer, bringing extensive experience in value-based care and healthcare technology. He will lead Evolent's 300-person medical team and report to CMO Dr. Von Nguyen.
John Way has been appointed as CFO of Performance Suite, overseeing financial aspects of the company's at-risk specialty condition management products. Way brings over 20 years of executive financial experience, including roles as CFO at OptumHealth and OptumCare, and will report to CFO John Johnson.
FAQ
What is the current stock price of Evolent Health (EVH)?
What is the market cap of Evolent Health (EVH)?
